Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10951278 | PMC |
| http://dx.doi.org/10.1038/s41416-024-02611-z | DOI Listing |
Publication Analysis
Top Keywords
comment "dexamethasone-sparing
4
"dexamethasone-sparing days
4
days 2-4
4
2-4 combined
4
combined palonosteron
4
palonosteron neurokinin-1
4
neurokinin-1 receptor
4
receptor antagonist
4
antagonist olanzapine
4
olanzapine cisplatin
4
Similar Publications
Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)".
Br J Cancer
April 2024
Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland.
Is the Dexamethasone-Sparing Strategy Ready For Cisplatin? Too Early For an Answer.
J Clin Oncol
September 2018
Luigi Celio, Fondazione IRCCS "Istituto Nazionale dei Tumori," Milan, Italy; Erminio Bonizzoni, University of Milan, Milan, Italy; and Matti Aapro, Genolier Cancer Center, Genolier, Switzerland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!